Avalyn Pharma (AVLN) Stock Overview

Operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. More details

AVLN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Makes less than USD$1m in revenue ($0)

Less than 3 years of financial data is available

AVLN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

UNCYFeatured

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.

View narrative

stuart_roberts

Community Contributor

US$21.53FV • 64.4% undervalued

5419.8%Revenue growth p.a.

6.2k

126

3mo ago

Avalyn Pharma Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Avalyn Pharma
Historical stock prices
Current Share Price	US$29.84
52 Week High	US$30.20
52 Week Low	US$26.00
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	65.78%

Recent updates

Shareholder Returns

	AVLN	US Pharmaceuticals	US Market
7D	n/a	3.3%	0.8%
1Y	n/a	27.3%	27.7%

Return vs Industry: Insufficient data to determine how AVLN performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how AVLN performed against the US Market.

Price Volatility

Is AVLN's price volatile compared to industry and market?
AVLN volatility
AVLN Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.3%

Stable Share Price: AVLN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine AVLN's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2010	50	Lyn Baranowski	www.avalynpharma.com

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis.

Avalyn Pharma Inc. Fundamentals Summary

How do Avalyn Pharma's earnings and revenue compare to its market cap?
AVLN fundamental statistics
Market cap	US$1.23b
Earnings (TTM)	-US$85.20m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-14.6x

P/E Ratio

Is AVLN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AVLN income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$85.20m
Earnings	-US$85.20m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-2.04
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did AVLN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/01 13:48
End of Day Share Price	2026/05/01 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Avalyn Pharma Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Avalyn Pharma Inc.NasdaqGS:AVLN Stock Report